Urinary neopterin and microalbuminuria in patients treated by low-density lipoprotein apheresis

Pteridines

Volumn 16, Issue 4, 2005, Pages 174-183

  Cermanová, Melanie ^a   Melichar, Bohuslav ^a   Solichová, Dagmar ^a   Bláha, Milan ^a   Blâha, Vladimír ^a   Blazek, Martin ^a   Mašín, Vladimír ^a   Cerman, Jaroslav ^a   Zadák, Zdenek ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Cholesterol; Familial hypercholesterolemia; LDL apheresis; Microalbuminuria; Neopterin

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEOPTERIN; TRIACYLGLYCEROL;

ADULT; APHERESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MACROPHAGE ACTIVATION; MALE; MICROALBUMINURIA; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME; URINALYSIS;

EID: 31444453298     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2005.16.4.174     Document Type: Article

References (51)

1. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61
2. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture. Circulation 1994; 90: 775-778
3. Falk E. Morphological features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 1989; 63: 114E-120E
4. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999; 19: 2355-63
5. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310-6
6. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27: 81-141
7. Baier-Bitterlich G, Fuchs D, Wachter H. Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Biochem Pharmacol 1997; 53: 755-763
8. Auzeby A, Bogdan A, Krosi Z, Touitou Y. Time-dependence of urinary neopterin, a marker of cellular immune activity. Clin Chem 1988; 34: 1866-7
9. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Stenohypothesis. Diabetologia 1989; 32: 219-226
10. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-7
11. Berton G, Cordiano R, Mbaso S, De Toni R, Mormino P, Palatini P. Prognostic significance of hypertension and albuminuria for early mortality after acute myocardial infarction. J Hypertens 1998; 16: 525-530
12. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, et al. Urine albumine/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Am Heart J 2002; 143: 319-326
13. Dell'omo G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R: Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men. J Intern Med 2003; 254: 76-84
14. Diercks GF, van Boven AJ, Hillege HL, Janssen WM, Kors JA, de Jong PE, et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population: the PREVEND study. Eur Heart J 2000; 21: 1922-1927
15. Nakayama T, Date C, Yokoyama T, Yoshiike N, Yamaguchi M, Tanaka H. A 15,5-year follow-up study of stroke in a Japanese provincial city: the Shibata Study. Stroke 1997; 28: 45-52
16. Beamer MB, Coull BM, Clark WM, Wynn M. Microalbuminuria in ischemic stroke. Arch Neurol 1999; 56: 699-702
17. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrels TJ. Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabet Med 1984; 1: 17-19
18. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington diabetes survey. Lancet 1988; 2: 530-533
19. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297-300
20. Lekatsas I, Kranidis A, Ioannidis G, Kalofoutis C, Tavernarakis A, Thalassinos N, et al. Comparison of the extent and severity of coronary artery disease in patients with acute myocardial infarction with and without microalbuminuria. Am J Cardiol 2004; 94: 334-337
21. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis 2003; 42: 466-73
22. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82
23. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-5
24. Goldstein, J., Hobbs, H., and Brown, M. Familial hypercholesterolemia. In: C. Scriver, A. Beaudet, W. Sly, and D. Valle, eds. The metabolic and molecular bases of inherited disease. McGraw-Hill New York. 2001; 2863-2913
25. Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, Hishida H, Nomura M et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 2002; 40: 220-7
26. Klingel R, Fassbender T, Fassbender C, Gohlen B. From membrane differential filtration to lipid filtration: technological progress in low-density lipoprotein apheresis. Ther Apher Dial 2003; 7: 350-8
27. Solichova D, Melichar B, Blaha V, Klejna M, Vavrova J, Palicka V, Zadak Z. Biochemical profile and survival in nonagenarians. Clin Biochem 2001; 34: 563-9
28. Weiss G, Willeit J, Kiechl S, Fuchs D, Jarosch E, Oberhollenzer F, et al. Inreased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis 1994; 106: 263-271
29. Schumacher M, Eber B, Tatzber F, Kaufmann P, Esterbauer H, Klein W. Neopterin levels in patients with coronary artery disease. Atherosclerosis 1992; 94: 87-88
30. Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Waeg G, et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991; 89: 203-208.
31. Melichar B, Gregor J, Solichova D, Lukes J, Tichy M, Pidrman V. Increased urinary neopterin in acute myocardial infarction. Clin Chem 1994; 40: 338-339
32. Gupta S, Fredericks S, Schwartzman RA, Holt DW, Kaski JC. Serum neopterin in acute coronary syndromes. Lancet 1997; 349: 1252-1253
33. Gurfinkel EP, Scirica BM, Bozovich G, Macchia A, Manos E, Mautner B. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1999; 83: 515-8
34. Garcia-Moll X, Cole D, Zouridakis E, Kaski JC. Increased serum neopterin: a marker of coronary artery disease activity in women. Heart 2000; 83: 346-50
35. Avanzas P, Arroyo-Espliquero R, Cosin-Sales J, Quiles J, Zouridakis E, Kaski JC. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary arthery disease. Am J Cardiol 2004; 93: 627-9
36. Van Haelst PL, Liem A, van Boven AJ, Veeger NJ, van Veldhuisen DJ, Tervaert JW, et al. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol 2003; 92: 1201-3
37. Forsblad J, Gottsater A, Persson K, Jacobsson L, Lindgrade F. Clinical manifestations of atherosclerosis in elderly population are related to plasma neopterin, NGAL and endothelin-1, but not to Chlamydia pneumoniae serology. Int Angiol 2002; 21: 173-9
38. Rudzite V, Jurika E, Schroecksnadel K, Kalnins U, Erglis A, Trusinskis K. Usefulness of neopterin, C-reactive protein, homocysteine, pyridoxal-5- phosphate, and phospholipid determination in coronary artery disease. Pteridines 2005; 16: 15-21
39. Couffinhal T, Dupláa C, Labat L, Moreau C, Bietz I, Bonnet J. Effect of low density lipoprotein on monocyte adhesiveness to endothelial cells in vitro. Atherosclerosis 1993; 99: 33-45
40. Frostergard J, Wu R, Haegerstrand A, Pattaroyo M, Lefvert AK, Nilson J. Mononuclear cells exposed to oxidized low density lipoproteins secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis 1993; 103: 213-219
41. Cattin L, Petrucco A, Cazzalato G, Bon GB, Borelli V, Nardon E, et al. Low density liprotein apheresis decreases oxidized low density lipoproteins and monocyte adhesion to endothelial cells. ASSAIO J 1997; 43: 209-213
42. Sampietro T, Tuoni M, Ferdeghini M, Ciardi A, Marraccini P, Prontera C, et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 1997; 96: 1381-5
43. Empen K, Otto C, Brodl UC, Parhofer KG. The effects of three different LDL-apheresis methods on plasma concentration of E-selectin, VCAM-1 and ICAM-1. J Clin Apheresis 2002; 17: 38-43
44. Blaha M, Krejsek J, Blaha V, Andrys J, Vokurkova D, Maly J et al. Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity. Physiol Res 2004; 53: 273-8
45. Neurauter G, Wirleitner B, Laich A, Schennach H, Weiss G, Fuchs D. Atrovastatin supresses interferon-γ-induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and monocytic cell lines. Clin Exp Immunol 2003; 131: 264-267
46. Van Haelst PL, van Doormaal JJ, May JF, Gans RO, Crijns HJ, Cohen Tervaert JW. Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Eur J Intern Med 2001; 12: 503-509
47. Vrecko K, Walzl M, Tafeit E, Reibnegger G. Relationship among serum and urine neopterin, fibrinogen, and other serum analytes in atherosclerotic patients and long-term effect of H.E.L.P. therapy. Pteridines 1999; 10: 190-196
48. Tanaka, T, Nakamura Y, Nasuno A, Mezaki T, Higuchi K, Fukunaga H, et al. Plasma concentrations of monocyte chemoattractant protein 1 (MCP-1) and neopterin in the coronary circulatin of patients with coronary artery disease. Circ J 2004; 68: 114-120
49. Sinzinger H, Kritz H. LDL-apheresis improves microalbuminuria in patients with severe familial heterozygous hypercholesterolemia. Atherosclerosis 1999; 143: 223-4
50. Zouvanis M, Raal FJ, Joffe BI, Seftel HC. Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 1995; 113: 289-92
51. Shankar A, Klein R, Moss SE, Klein BE, Wong TY. The relationship between albuminuria and hypercholesterolemia. J Nephrol 2004; 17: 658-65